Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies
| Autor: | Simranjeet Singh Grewal, Joseph J. Smith, Amanda-Jayne F. Carr |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Ophthalmology, Vol 13 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2515-8414 25158414 |
| DOI: | 10.1177/2515841421997191 |
| Popis: | Bestrophinopathies are a group of clinically distinct inherited retinal dystrophies that typically affect the macular region, an area synonymous with central high acuity vision. This spectrum of disorders is caused by mutations in bestrophin1 ( BEST1 ), a protein thought to act as a Ca 2+ -activated Cl - channel in the retinal pigment epithelium (RPE) of the eye. Although bestrophinopathies are rare, over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance. With no current clinical treatments available for patients with bestrophinopathies, understanding the role of BEST1 in cells and the pathological pathways underlying disease has become a priority. Induced pluripotent stem cell (iPSC) technology is helping to uncover disease mechanisms and develop treatments for RPE diseases, like bestrophinopathies. Here, we provide a comprehensive review of the pathophysiology of bestrophinopathies and highlight how patient-derived iPSC-RPE are being used to test new genomic therapies in vitro. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|